Artiva is evaluating AlloNK across multiple autoimmune indications through several clinical programs, including a Phase 2a basket trial that tests a single therapy across related diseases. That ongoing study is examining AlloNK, in combination with rituximab, in refractory rheumatoid arthritis (RA), Sjögren’s disease (SjD), idiopathic inflammatory myopathies (IIMs), and systemic sclerosis (SSc). The trial received FDA clearance in May, with patient dosing beginning in August. In parallel, Artiva is running ...